AI Article Synopsis
- - Sphingosine-1-phosphate (S1P) is a crucial signaling molecule involved in various bodily functions and conditions, including immune response and potential cancer risks, by activating S1P receptors 1 through 5.
- - Researchers are exploring S1P receptor agonists, like fingolimod and ozanimod, as new treatments for ulcerative colitis (UC) by preventing lymphocytes from leaving lymph nodes.
- - Selective S1P modulators are being developed to improve the effectiveness and safety of S1P-based treatments, with ongoing Phase 3 trials expected to provide further evidence of their benefits for UC management.
Article Abstract
: Sphingosine-1-phosphate (S1P) is a membrane-derived lysophospholipid signaling molecule implicated in various physiological and pathological processes, such as regulation of the immune, cardiovascular, pulmonary, and nervous systems and theoretical cancer-related risks, through extracellular activation of S1P1-5 receptors.: S1P receptor agonism is a novel strategy for the treatment of UC targeting lymphocyte recirculation, through blockade of lymphocyte egress from lymph nodes. We conducted an extensive literature review on PUBMED on currently available data on molecular aspects of S1P modulation, the mechanisms of action of S1PR agonists (fingolimod, ozanimod, etrasimod, and KRP-203), and their potential efficacy and safety for the treatment of patients with ulcerative colitis.: Selective S1P modulators have emerged to enlarge the efficacy and safety profile of this class of agents. Phase 3 programs should add the potential body of evidence to prove their benefit for the management of UC patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14712598.2020.1732919 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!